SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Designed to Heal

Early Healing

Freedom From Long-term Polymer Exposure

Clinical Program

Patient and Physician Experiences

Synchrony™ Bioabsorbable Polymer Coating

Discover why Dr. Antonio Colombo from San Rafaelle in Milan, Italy uses SYNERGY in his daily practice

SYNERGY Stent engineers explain the science behind the design

OCT study of LAD stents 2-months post-implant

High Bleeding Risk Indication
Now CE Marked

Synergy 4.5mm & 5.0mm

Healing Viewed Through Angioscopy

Synchrony™ Bioabsorbable Polymer Coating is applied only to the abluminal side of the stent to stimulate healthy endothelialization.

Discover why Dr. Antonio Colombo from San Rafaelle in Milan, Italy uses SYNERGY in his daily practice.

SYNERGY Stent engineers explain the science behind the design goal to provide optimal healing and to improve patient outcomes, among all types of complexities.

This OCT study of LAD stents 2-months post-implant show consistent, full strut coverage of the SYNERGY Stent compared to a bioabsorbable vascular scaffold (BVS).*

The SYNERGY Stent is designed so its attributes synergistically work together to promote optimal healing within the vessel.¹

Join our COMPLEX PCI COMMUNITY

Request a Sales Rep

Submit Your Questions

EVOLVE II Clinical Trial Data

Learn on Educare

Explore

Product Details

Because you never know when life will become complex

Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures. Still, there remains a concern for being able to treat ever-increasing complex lesions, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).

What if there was a technology that offered the benefits of being able to improve the ability to acutely treat complex lesions, improve the healing properties, and potentially free selected patients from long-term DAPT?**

Introducing the SYNERGY Stent

Designed to help patients, including those with complex cases, heal from day one and beyond.

Designed to Heal

Abluminally-coated stent technology synchronizes the release of drug elution and polymer absorption for optimal healing within the vessel.¹

Learn more

Early Healing

The SYNERGY Stent’s ultra-thin struts show more rapid healing compared to thicker stent strut designs in clinical cases and in preclinical research.^2,3

Learn more

Freedom from Long-Term Polymer Exposure

Polymer is gone when it’s no longer needed—shortly after the drug is completely eluted at three months, which minimizes polymer exposure in the vessel.⁴

Learn more

Ordering Information

	STENT LENGTH
ø (mm)	8	12	16	20	24	28	32	38	48	Over Expansion Capability
2.25	H7493926208220	H7493926212220	H7493926216220	H7493926220220	H7493926224220	H7493926228220	H7493926232220	H7493926238220		3.50
2.50	H7493926208250	H7493926212250	H7493926216250	H7493926220250	H7493926224250	H7493926228250	H7493926232250	H7493926238250	H7493926248250	3.50
2.75	H7493926208270	H7493926212270	H7493926216270	H7493926220270	H7493926224270	H7493926228270	H7493926232270	H7493926238270	H7493926248270	3.50
3.00	H7493926208300	H7493926212300	H7493926216300	H7493926220300	H7493926224300	H7493926228300	H7493926232300	H7493926238300	H7493926248300	4.25
3.50	H7493926208350	H7493926212350	H7493926216350	H7493926220350	H7493926224350	H7493926228350	H7493926232350	H7493926238350	H7493926248350	4.25
4.00	H7493926208400	H7493926212400	H7493926216400	H7493926220400	H7493926224400	H7493926228400	H7493926232400	H7493926238400	H7493926248400	5.75
4.50		H7493926212450	H7493926216450	H7493926220450	H7493926224450	H7493926228450	H7493926232450			5.75
5.00		H7493926212500	H7493926216500	H7493926220500	H7493926224500	H7493926228500	H7493926232500			5.75

Clinical Information

SYNERGY Stent Clinical Program and Research

Addressing the full spectrum of cardiovascular disease complexity

The SYNERGY Stent design goals are to address needs surrounding complex PCI. As a result, Boston Scientific established a robust clinical trial program and is supporting investigator-sponsored research⁵ (ISR) that will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice.

Clinical Program and Research

SYNERGY™ Stent

EVOLVE Clinical Trials Overview

EVOLVE II Clinical Trial 3-Year Data

Supporting Research of the SYNERGY Stent

Complex Lesions

The SYNERGY Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease, including patients with acute myocardial infarction and patients with concomitant diabetes mellitus due to discrete de novo native coronary artery lesions. The SYNERGY Stent System is also indicated for treatment of patients presenting with:

Added recommendations include: For treatment of occluded vessels, contrast visualization of the distal vessel to confirm position of guidewire within the lumen is recommended. For in stent restenosis, where details of the original stent are known, the expanded inner diameter of the new stent should not exceed the dilation limits of the original stent. Where details of the original stent are not known, the expanded inner diameter of the new stent should not exceed the reference vessel diameter. When treating Bifurcations, care must be exercised to access the secondary vessel via the repeating geometry in the body of the stent within the primary vessel.

SYNERGY DAPT Labelling Update - Now CE Marked

Long Lesions

Watch Video

Heal Long Lesions with Confidence

Long Lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time.*** SYNERGY™ BP Stent was designed for quality healing and safety over time. With the addition of a 48mm length SYNERGY has a complete size matrix to address these complex lesions.The SYNERGY™ BP Stent, with its abluminal, bioabsorbable polymer, shows more complete stent coverage compared to permanent polymer stents.

Not yet a member of the Complex PCI Community?

and stay up to date with the latest advances for optimizing revascularization

^ The updated Directions for Use will also include an update on the current “Pre-and Post-Procedure Antiplatelet Regimen”:
In selected higher risk patients where the physician determines that the risks outweigh the benefits of continued DAPT, it may be reasonable to interrupt or discontinue therapy after 1 month based on low stent thrombosis rates and no observed increased risk for stent thrombosis as shown in the current literature. Patients who require premature discontinuation of antiplatelet therapy should be monitored closely and have their antiplatelet therapy restarted as soon as possible per the discretion of their treating physicians.

Top